



# Biotech Daily

Friday August 5, 2016

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: OPTHEA UP 6%, ANTEO DOWN 5%**
- \* **WEHI LAUNCHES HAEMOPAEDIA MOUSE BLOOD TYPE DATABASE**
- \* **ONE FUNDS INCREASES, DILUTED TO 8% OF AVITA**
- \* **REGENEUS PLEADS SCHULTZ TO ASX 29% QUERY**
- \* **MEDIBIO REQUESTS 'DATA VALIDATION RESULTS' TRADING HALT**
- \* **TBG DELISTS FROM THE US OTC MARKET**

## MARKET REPORT

The Australian stock market was up 0.39 percent on Friday August 5, 2016 with the ASX200 up 21.6 points to 5,497.4 points.

Nineteen of the Biotech Daily Top 40 stocks were up, 10 fell, seven traded unchanged and four were untraded.

Opthea was the best, up 3.5 cents or 5.8 percent to 64 cents with 142,207 shares traded.

Airxpanders, Neuren, Pharmaxis and Universal Biosensors climbed five percent or more; Benitec was up 4.55 percent; Prima rose 2.5 percent; Cochlear, Ellex, Impedimed, Living Cell, Orthocell and Pro Medicus were up more than one percent; with Acrux, Clinuvel, Mesoblast, Nanosonics, Reva, Resmed, Sirtex and Starpharma up less than one percent.

Anteo led the falls, down 0.3 cents or 5.3 percent to 5.4 cents with 2.6 million shares traded.

Atcor, Biotron and Prana lost more than three percent; IDT, Medical Developments and Viralytics shed more than two percent; Actinogen, Admedus and Avita were down more than one percent; with CSL down 0.05 percent.

### THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says its staff have developed and launched an online database of mouse blood cell types.

The Institute said that the Haemopaedia database mapped the expression of the body's 20,000 genes in 54 different blood cell types, which allows users to access, analyze and cross-reference research data which is freely available to the public as well as the scientific community.

WEHI said that Dr Carolyn de Graaf led a team of researchers who developed Haemopaedia, which was supported by a web portal called Haemosphere ([www.haemosphere.org](http://www.haemosphere.org)).

"Our blood cells hold critical clues about our bodies in health and in disease," Dr de Graaf said.

"This resource will help scientists across the world to discover patterns of gene expression that show how particular cells may be targeted by drugs," Dr de Graaf said.

The Institute said that research underlying the database entitled 'Haemopedia: An Expression Atlas of Murine Hematopoietic Cells' was published in Stem Cell Reports, and was at: [http://www.cell.com/stem-cell-reports/fulltext/S2213-6711\(16\)30131-X](http://www.cell.com/stem-cell-reports/fulltext/S2213-6711(16)30131-X).

### AVITA MEDICAL

One Funds Management says it has increased its holding in Avita from 41,129,032 shares but has been diluted from 10.11 percent to 8.34 percent.

The Sydney-based One Funds Asia-Pac Healthcare Fund II account said it acquired 13,440,860 shares for \$1,250,000 or 9.3 cents a share in a placement that raised \$10,018,644 in October 2015 and 1,555,555 shares for \$140,000 or nine cents a share in a recent rights issue which raised \$9,014,835 (BD: Oct 20, 2015; Jul 11, 2016).

The Melbourne-based Bioscience Managers (formerly IB Managers) website said that the Asia Pacific Healthcare Fund II was a 10-year Australian unit trust equity style fund of \$55 million, with One Funds a Bioscience Managers trustee.

Avita fell 0.1 cents or 1.1 percent to 9.2 cents.

### REGENEUS

Regeneus has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 29.2 percent from 12 cents on August 4 to 15.5 cents on August 5, 2016 and noted an increase in trading volume.

Regeneus said it had told the market on July 1, 2016 that it was in discussions with potential partners in Japan for the manufacture clinical development and commercialization of its Progenza product which "could be expected to have a positive effect on the price of [its] securities" if successful.

The company said that the discussions were "on-going and incomplete".

Regeneus closed up 2.5 cents or 20.8 percent at 14.5 cents with 1.4 million shares traded.

### MEDIBIO (FORMERLY BIOPROSPECT)

Medibio has requested a trading halt "pending the announcement of data validation results".

Trading will resume on August 9, 2016 or on an earlier announcement.

Medibio last traded at 32.5 cents.

#### TBG DIAGNOSTICS (FORMERLY PROGEN PHARMACEUTICALS)

TBG says it will file a voluntarily terminate its reporting obligations to the US Securities and Exchange Commission, effectively delisting from the US markets.

TBG company secretary Blair Lucas told Biotech Daily that the filing was effectively deregistration from the US over-the-counter market, initiated when the company was Progen Pharmaceuticals and would be a reduction in regulatory burden, saving shareholder funds.

TBG said that the termination was expected to become effective no later than 90 days after the filing, if there were no objections from the Commission.

TBG was unchanged at 20.5 cents.